Press coverage about Momenta Pharmaceuticals (NASDAQ:MNTA) has trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Momenta Pharmaceuticals earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.3983953774119 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Momenta Pharmaceuticals, Inc. (markets.financialcontent.com)
- Here's Why Momenta Pharmaceuticals, Inc. Reversed Course Today (finance.yahoo.com)
- Here’s Why Momenta Pharmaceuticals, Inc. Reversed Course Today (fool.com)
- Momenta Pharmaceuticals, Inc. (MNTA) Receives Consensus Recommendation of “Hold” from Brokerages (americanbankingnews.com)
- Momenta Phama (MNTA) Announces Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281 (streetinsider.com)
MNTA has been the subject of several recent analyst reports. Goldman Sachs Group initiated coverage on shares of Momenta Pharmaceuticals in a research note on Thursday, September 28th. They set a “neutral” rating and a $18.00 price objective for the company. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Robert W. Baird downgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their price objective for the company from $22.00 to $15.00 in a research note on Friday, October 6th. Cowen set a $15.00 price objective on shares of Momenta Pharmaceuticals and gave the company a “hold” rating in a research note on Wednesday, November 1st. Finally, BidaskClub downgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company. Momenta Pharmaceuticals has an average rating of “Hold” and an average target price of $15.00.
Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.03. Momenta Pharmaceuticals had a negative net margin of 55.61% and a negative return on equity of 16.20%. The company had revenue of $24.09 million during the quarter, compared to the consensus estimate of $29.58 million. During the same period in the prior year, the firm earned ($0.26) earnings per share. Momenta Pharmaceuticals’s revenue was down 17.3% on a year-over-year basis. equities analysts predict that Momenta Pharmaceuticals will post -1.16 EPS for the current fiscal year.
In related news, Director Elizabeth Stoner sold 5,500 shares of the stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $13.10, for a total value of $72,050.00. Following the completion of the transaction, the director now directly owns 13,240 shares of the company’s stock, valued at $173,444. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Craig A. Wheeler sold 35,666 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $14.11, for a total transaction of $503,247.26. The disclosure for this sale can be found here. Over the last three months, insiders sold 49,505 shares of company stock valued at $685,923. 4.40% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: “Momenta Pharmaceuticals (MNTA) Given News Impact Score of 0.13” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.com-unik.info/2018/01/11/momenta-pharmaceuticals-mnta-given-news-impact-score-of-0-13.html.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.